Cytodyn Inc (CYDY)

[BlackDoggie]

Fair point, and I don't know the answer to the question. Truthfully, I believe the safety aspect (beyond helping the approval process immensely) is less impactful to combo than mono, etc. The FDA essentially required the company to do a combo trial as a prerequisite for pursuing mono. Why? The combo population (multi-drug resistance) is an unmet medical need - they're running out of existing treatment options. Patients in that space are at high risk of transmitting the virus and/or experiencing life-threatening disease progression. If you can help that population, side effects are something of an afterthought.

On the other hand, the lack of adverse effects is going to be a MASSIVE selling point in the mono, cancer, and GvHD markets.